Jun Guo
About
Jun Guo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Jun Guo has authored 208 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Oncology, 96 papers in Molecular Biology and 61 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jun Guo's work include Cutaneous Melanoma Detection and Management (63 papers), Cancer Immunotherapy and Biomarkers (57 papers) and Melanoma and MAPK Pathways (56 papers). Jun Guo is often cited by papers focused on Cutaneous Melanoma Detection and Management (63 papers), Cancer Immunotherapy and Biomarkers (57 papers) and Melanoma and MAPK Pathways (56 papers). Jun Guo collaborates with scholars based in China, United States and Ethiopia. Jun Guo's co-authors include Lu Si, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Lili Mao, Yan Kong, Bin Lian, Jie Dai, Bixia Tang and Xieqiao Yan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Jun Guo
193 papers receiving 3.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jun Guo China | 30 | 2.3k | 1.7k | 820 | 642 | 519 | 208 | 3.5k | ||
| Luis de la Cruz‐Merino Spain | 26 | 2.6k 1.1× | 1.9k 1.2× | 812 1.0× | 703 1.1× | 541 1.0× | 175 | 4.0k | ||
| Asma Tulbah Saudi Arabia | 31 | 1.9k 0.9× | 880 0.5× | 765 0.9× | 533 0.8× | 837 1.6× | 104 | 3.3k | ||
| Karim A. Benhadji United States | 32 | 2.1k 0.9× | 1.8k 1.1× | 669 0.8× | 539 0.8× | 540 1.0× | 117 | 3.8k | ||
| Bo Dai China | 32 | 1.1k 0.5× | 1.4k 0.9× | 580 0.7× | 1.3k 2.0× | 1.0k 1.9× | 144 | 3.3k | ||
| Samia Mourah France | 33 | 1.3k 0.6× | 1.5k 0.9× | 582 0.7× | 280 0.4× | 431 0.8× | 162 | 3.1k | ||
| Miguel Á. Idoate Spain | 28 | 1.1k 0.5× | 809 0.5× | 544 0.7× | 690 1.1× | 458 0.9× | 146 | 3.2k | ||
| Sha Zhao China | 30 | 1.4k 0.6× | 1.5k 0.9× | 1.2k 1.4× | 785 1.2× | 745 1.4× | 97 | 3.4k | ||
| Pierosandro Tagliaferri Italy | 34 | 1.7k 0.7× | 1.1k 0.7× | 645 0.8× | 449 0.7× | 615 1.2× | 97 | 3.2k | ||
| Hussein A. Tawbi United States | 32 | 3.0k 1.3× | 1.3k 0.8× | 1.3k 1.6× | 1.4k 2.1× | 303 0.6× | 152 | 4.3k | ||
| Lisa Zimmer Germany | 33 | 3.1k 1.4× | 1.5k 0.9× | 987 1.2× | 644 1.0× | 169 0.3× | 155 | 4.3k |
Countries citing papers authored by Jun Guo
Since
Specialization
Citations
This map shows the geographic impact of Jun Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Guo more than expected).
Fields of papers citing papers by Jun Guo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jun Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Guo. The network helps show where Jun Guo may publish in the future.
Co-authorship network of co-authors of Jun Guo
This figure shows the co-authorship network connecting the top 25 collaborators of Jun Guo. A scholar is included among the top collaborators of Jun Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Guo. Jun Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Guo, Jun, et al.. (2025). Metabolic Syndrome-Associated Erectile Dysfunction: Multiple Vascular Endothelial Dysfunction Mechanisms and Potential Therapeutic Targets. International Journal of Biological Sciences. 21(13). 5842–5858.
2.
Arance, Ana, Miguel‐Ángel Berciano‐Guerrero, Jun Guo, et al.. (2025). Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Annals of Oncology. 36(12). 1535–1546.
3.
Gu, Junjie, Jun Guo, Yu Jiang, et al.. (2024). FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1mutations: A phase 1B dose-expansion study.. Journal of Clinical Oncology. 42(16_suppl). 3095–3095.
4.
Tang, Bixia, Rong Duan, Xieqiao Yan, et al.. (2024). Natural history of bone-only metastasis in renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 42(4). 119.e17–119.e22.
5.
Yang, Kaiwei, Hang Huang, Xue Bai, et al.. (2024). Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.. Journal of Clinical Oncology. 42(16_suppl). 4568–4568.
6.
Dai, Jie, Fanshuang Zhang, Yanfeng Xi, et al.. (2024). Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications. Cancer Research Communications. 4(5). 1351–1362.
7.
Tang, Bixia, Rong Duan, Xiaoshi Zhang, et al.. (2024). Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. The Oncologist. 29(6). e822–e827.
8.
Li, Siming, Yanxia Shi, Haiying Dong, et al.. (2024). Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China. Cancer Medicine. 13(21). e70368–e70368.
9.
Guo, Qian, Jianjian Zhang, Yaling Huang, et al.. (2023). A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma. Cancer Research. 83(22). 3783–3795.
10.
Cui, Chuanliang, Yu Chen, Zhiguo Luo, et al.. (2023). Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. BMC Cancer. 23(1). 121–121.
11.
Li, Siming, Xiaowen Wu, Xieqiao Yan, et al.. (2022). Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. Journal for ImmunoTherapy of Cancer. 10(2). e004036–e004036.
12.
Bai, Xue, Michelle Kim, Gyulnara G. Kasumova, et al.. (2021). Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. Journal for ImmunoTherapy of Cancer. 9(2). e002092–e002092.
13.
Yan, Xieqiao, Xinan Sheng, Zhihong Chi, et al.. (2021). Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology. 39(8). 881–889.
14.
Bai, Xue, Yan Kong, Zhihong Chi, et al.. (2017). MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research. 23(20). 6120–6127.
15.
Chang, John Wen‐Cheng, Jun Guo, Chia‐Yen Hung, et al.. (2017). Sunrise in melanoma management: Time to focus on melanoma burden in Asia. Asia-Pacific Journal of Clinical Oncology. 13(6). 423–427.
16.
Kong, Yan, Lu Si, Yiqian Li, et al.. (2015). Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors. Clinical Cancer Research. 22(4). 1018–1027.
17.
Dai, Jie, Yan Kong, Lu Si, et al.. (2013). Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib. Clinical Cancer Research. 19(24). 6935–6942.
18.
Lian, Bin, Lu Si, Chuanliang Cui, et al.. (2013). Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 19(16). 4488–4498.
19.
Si, Lu, Yanyan Zhu, Xiaowei Xu, et al.. (2011). Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clinical Cancer Research. 17(7). 1684–1691.
20.
Cheng, Xiaoguang, Hui Qu, Wei Liu, et al.. (2005). The prevalence of osteonecrosis in severe acute respiratory syndrome patients: an MRI screening study. Zhonghua fangshexian yixue zazhi. 39(8). 791–797.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Luis de la Cruz‐Merino Breakdown of academic impact, for papers by Asma Tulbah Breakdown of academic impact, for papers by Karim A. Benhadji Breakdown of academic impact, for papers by Bo Dai Breakdown of academic impact, for papers by Samia Mourah Breakdown of academic impact, for papers by Miguel Á. Idoate Breakdown of academic impact, for papers by Sha Zhao Breakdown of academic impact, for papers by Pierosandro Tagliaferri Breakdown of academic impact, for papers by Hussein A. Tawbi Breakdown of academic impact, for papers by Lisa Zimmer